Vanderbilt, GE-developed AI Predicting Immunotherapy Responses
7 March 2024
Fierce Biotech is reporting on a collaborative effort of GE HealthCare and Vanderbilt University Medical Center. An Artificial Intelligence (AI) they have developed has been used to study medical records and patient data (such as whether the patient was a smoker), to determine the effectiveness of immunotherapy treatments. 2,200 Vanderbilt patients' data were studied, across various forms of cancer and treatments.
GE tells Fierce Biotech that: "...the algorithms were able to deliver 70% to 80% accuracy in forecasting efficacy outcomes and the likelihood of unwanted side effects..."
